Insulin Syringes

Insulin Syringes Market Outlook

The global insulin syringes market is projected to reach USD 3.35 billion by 2035, growing at a CAGR of approximately 5.6% during the forecast period from 2025 to 2035. This growth can be attributed to factors such as the increasing prevalence of diabetes globally, rising awareness about diabetes management, and advancements in insulin delivery systems. The surge in the geriatric population, who are more susceptible to diabetes, further fuels demand for effective insulin management solutions. Additionally, the growing preference for user-friendly and safer injection methods, particularly with safety syringes, is expected to enhance market prospects. Moreover, the rise in health initiatives promoting diabetes education and management is likely to support the expansion of the insulin syringes market.

Growth Factor of the Market

The insulin syringes market is experiencing substantial growth, driven primarily by the increasing incidence of diabetes worldwide. As per the International Diabetes Federation, the number of adults living with diabetes has escalated from 108 million in 1980 to 537 million in 2021, with projections estimating it could reach 783 million by 2045. This alarming rise necessitates effective management solutions, including the use of insulin syringes. Additionally, advancements in syringe designs, such as the introduction of smart insulin syringes, have significantly improved the patient experience by ensuring accurate dosing and reducing the risk of needle stick injuries. The growing adoption of telemedicine and digital health solutions is also contributing to the market growth, as patients increasingly seek convenient and accessible diabetes management tools. Furthermore, government initiatives aimed at improving diabetes care and access to treatment options play a crucial role in expanding the insulin syringes market, particularly in developing regions.

Key Highlights of the Market

• The global insulin syringes market is set to witness a growth rate of 5.6% CAGR from 2025 to 2035.
• Innovative product types, such as safety and smart insulin syringes, are gaining traction for their added convenience and safety features.
• The expanding diabetic patient population is a major driver, with significant growth identified across all major regions.
• Online pharmacies and home healthcare channels are emerging as important distribution avenues, especially post-pandemic.
• Government policies focused on diabetes management will likely drive increased accessibility and affordability of insulin syringes.

By Product Type

Standard Insulin Syringes:

Standard insulin syringes have long been the traditional mode of insulin delivery for diabetic patients. These syringes typically come in various sizes, allowing users to accurately measure their insulin doses based on their specific requirements. Their widespread availability and cost-effectiveness continue to make them a popular choice among patients and healthcare providers. The simplicity of using standard insulin syringes contributes to their sustained demand, particularly in regions where advanced delivery systems may not be as accessible. Despite the introduction of newer technologies, standard syringes remain a cornerstone of diabetes care, especially among those who prefer conventional methods of insulin administration.

Safety Insulin Syringes:

Safety insulin syringes have gained significant attention in recent years due to their innovative design aimed at reducing the risk of needle stick injuries. These syringes come equipped with mechanisms that allow for automatic retraction of the needle after use, thereby providing a safer disposal option and minimizing the risk of accidental pricks. This feature is particularly appealing to healthcare providers and patients, as it enhances safety during administration and reduces the incidence of infections. As awareness of the importance of safety in healthcare practices rises, the demand for safety insulin syringes is expected to increase, contributing positively to market growth.

Smart Insulin Syringes:

Smart insulin syringes represent a revolutionary advancement in diabetes management, integrating technology with traditional insulin delivery methods. These syringes often feature connectivity options, allowing users to track their insulin doses via mobile applications or devices. This real-time data sharing not only enhances user adherence but also provides valuable insights into their insulin usage patterns, aiding in better management of their condition. As the healthcare sector shifts towards digital health solutions, the smart insulin syringe segment is anticipated to experience notable growth, particularly among tech-savvy patients and younger demographics.

Pen Needles:

Pen needles are designed for use with insulin pens, offering a convenient and portable insulin delivery option for many diabetic patients. These needles are favored for their ease of use and the ability to deliver accurate doses without the hassle of traditional syringes. As more patients transition to insulin pens, the market for pen needles is growing rapidly. The availability of different needle sizes and lengths makes them suitable for a wide range of users, providing flexibility and comfort during administration. This segment is projected to grow as more healthcare providers recommend insulin pens for their ease and convenience, particularly for patients in need of daily insulin administration.

Insulin Syringe with Needle:

Insulin syringes that come with a pre-attached needle offer a streamlined solution for patients, eliminating the need for separate needle attachment. This type of syringe is designed for single-use, improving convenience and reducing the likelihood of contamination. This feature is particularly beneficial for individuals who may struggle with the dexterity required to attach needles, making insulin administration simpler and safer. The rising popularity of these syringes can be linked to their user-friendly design, making them an ideal choice for the elderly and those with mobility challenges. As the market for insulin delivery continues to evolve, the insulin syringe with needle segment is expected to witness steady growth.

By Application

Type 1 Diabetes:

Type 1 diabetes is an autoimmune condition that results in the complete inability to produce insulin, necessitating lifelong insulin therapy for affected individuals. This segment significantly drives the insulin syringes market, as patients require consistent and precise insulin delivery to manage their blood glucose levels effectively. As a result, the demand for various insulin delivery methods, including syringes, is expected to remain robust. Moreover, advancements in insulin formulations and delivery devices continue to enhance treatment options for these patients, further contributing to market growth.

Type 2 Diabetes:

Type 2 diabetes, characterized by insulin resistance and relative insulin deficiency, accounts for a substantial majority of diabetes cases worldwide. The management of this condition often involves lifestyle modifications, oral medications, and sometimes insulin therapy. As such, the insulin syringes market is influenced by the growing population of individuals diagnosed with Type 2 diabetes who require insulin injections. The awareness of the need for effective diabetes management solutions continues to drive the demand for insulin syringes, coupled with an increase in health education initiatives aimed at this demographic.

Gestational Diabetes:

Gestational diabetes occurs during pregnancy and usually resolves after giving birth, but it necessitates careful monitoring and management to ensure the health of both the mother and the baby. For some women, insulin therapy is required, leading to the need for suitable insulin delivery methods, including syringes. The increasing awareness and diagnosis of gestational diabetes are expected to boost the demand for insulin syringes, as healthcare providers ensure effective management strategies for expectant mothers. The market for this application is likely to see growth, particularly in regions where maternal health initiatives are promoted.

Insulin Resistance:

Insulin resistance is a condition where the body's cells become less responsive to insulin, often leading to Type 2 diabetes and other metabolic disorders. The management of insulin resistance may require insulin therapy, thereby driving the demand for insulin syringes. As awareness of this condition increases, particularly in the context of rising obesity rates and lifestyle-related health issues, the market for insulin syringes is anticipated to grow. Healthcare focus on preventive strategies and treatment options for insulin resistance is likely to be a significant contributor to this segment's growth.

Prediabetes:

Prediabetes is characterized by elevated blood sugar levels that are not yet high enough to be classified as Type 2 diabetes, but it poses a greater risk of developing diabetes in the future. The management of prediabetes often involves lifestyle changes, but in some cases, patients may require insulin therapy to maintain healthy glucose levels. This growing segment within the diabetes management landscape is likely to drive demand for insulin syringes as healthcare providers focus on preventing the progression of prediabetes into Type 2 diabetes. Awareness campaigns and health screenings for prediabetes are expected to further support growth in this area.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies play a critical role in the distribution of insulin syringes, as they are often the first point of care for patients diagnosed with diabetes. These pharmacies provide comprehensive medication management services, including education on proper insulin administration techniques. The presence of healthcare professionals in hospital settings allows for personalized guidance, which can enhance patient adherence to insulin therapy. As the number of hospitals increases and diabetes care becomes more centralized within healthcare institutions, the contribution of hospital pharmacies to the insulin syringes market is expected to grow steadily.

Retail Pharmacies:

Retail pharmacies serve as a convenient option for patients to obtain insulin syringes, offering accessibility and immediate availability of diabetes management supplies. These pharmacies often stock a variety of syringe types, catering to diverse patient needs. The rise of community pharmacies and their involvement in diabetes care services, such as counseling and monitoring, supports the growth of this segment. As patients increasingly seek accessible and affordable healthcare solutions, retail pharmacies are positioned to play a significant role in the overall insulin syringes market, contributing to an increased market share.

Online Pharmacies:

The emergence of online pharmacies has revolutionized the way patients acquire insulin syringes and other diabetes management supplies. This distribution channel provides unparalleled convenience for users, allowing them to order products from the comfort of their homes. Online pharmacies often offer competitive pricing and a wider selection of products, appealing to a tech-savvy and health-conscious consumer base. The COVID-19 pandemic has accelerated the adoption of online shopping for healthcare products, and this trend is expected to persist, making online pharmacies a crucial player in the insulin syringes market. As e-commerce continues to expand, the market share of online pharmacies is likely to increase significantly.

Diabetes Clinics:

Diabetes clinics specialize in providing comprehensive care and management strategies for individuals living with diabetes. These clinics often offer insulin syringes as part of their treatment plans, ensuring that patients have access to the necessary supplies for effective diabetes management. In addition to distributing syringes, diabetes clinics provide education, dietary planning, and ongoing support, making them invaluable resources for patients. As the demand for specialized diabetes care grows, the importance of diabetes clinics in the insulin syringes market is expected to rise, particularly among patients seeking holistic management approaches.

Home Healthcare:

The home healthcare sector has gained prominence as patients increasingly prefer receiving medical care in the comfort of their homes. This is particularly relevant for individuals with diabetes who may require regular insulin injections and monitoring. Home healthcare providers often supply insulin syringes to patients, ensuring they have the tools necessary for effective self-management. As the trend toward home healthcare continues to grow, driven by both patient preferences and advancements in telehealth, the demand for insulin syringes in this channel is expected to increase. The convenience of home healthcare services aligns with the broader goal of improving diabetes management and patient outcomes.

By Material Type

Plastic Insulin Syringes:

Plastic insulin syringes are among the most commonly used types due to their versatility and cost-effectiveness. These syringes are lightweight, disposable, and come in various sizes, catering to the diverse needs of diabetic patients. The use of plastic also minimizes the risk of breakage, making them safer for handling and disposal. Additionally, advancements in plastic materials have led to the development of syringes that provide improved accuracy in insulin delivery. The growing preference for disposable products will likely fuel the demand for plastic insulin syringes in the upcoming years, making them a staple in diabetes management.

Glass Insulin Syringes:

Glass insulin syringes are known for their durability and reusability, appealing to patients who prefer a more environmentally sustainable option. These syringes allow for precise measurement and are often preferred by patients who require careful dosing of their insulin. While less common due to the need for sterilization and proper care, glass syringes can be advantageous for individuals looking for cost-effective long-term solutions. The market for glass insulin syringes may see growth as awareness of sustainability and waste reduction efforts in healthcare increases, encouraging patients to consider reusable options.

Metal Insulin Syringes:

Metal insulin syringes are rarely used today, but they were once common in diabetes management. They are designed for durability and longevity, making them ideal for long-term use. However, their complexity in cleaning and the need for maintenance have led to a decline in popularity with the rise of disposable syringes. Nonetheless, metal syringes may find niche applications in specific patient populations or settings where reusability is a priority. While the overall market share for metal insulin syringes is limited, their presence remains a reminder of the evolution of insulin delivery methods over the years.

Disposable Insulin Syringes:

Disposable insulin syringes are widely favored among patients for their convenience and safety. These syringes are designed for single-use, reducing the risk of contamination and infections associated with reuse. Their cost-effectiveness and readiness for use without the need for sterilization make them an ideal choice for many diabetics. The increasing emphasis on safety and hygiene in healthcare practices is expected to bolster the demand for disposable insulin syringes, contributing positively to the overall market. As patients prioritize their health and well-being, disposable options are likely to dominate the insulin syringes market.

Reusable Insulin Syringes:

Reusable insulin syringes provide patients with a sustainable option for insulin delivery, allowing them to refill syringes and use them multiple times. This can be a more economical choice for long-term insulin users, particularly those who require insulin therapy for an extended period. However, the requirement for proper cleaning and maintenance may deter some users from opting for reusable syringes. The market for reusable insulin syringes is likely to see steady demand, especially among environmentally conscious patients and those seeking to reduce waste in their diabetes management practices.

By Region

The regional analysis of the insulin syringes market reveals significant variations in growth and demand across different areas. North America is currently the largest market for insulin syringes, accounting for nearly 40% of the global share. The high prevalence of diabetes and the presence of advanced healthcare infrastructure contribute to the robust demand for diabetes management tools in this region. Additionally, the increasing adoption of innovative insulin delivery methods, such as smart syringes and pen needles, is driving market expansion. The market in North America is anticipated to witness a steady CAGR of 5.8% from 2025 to 2035.

In Europe, the insulin syringes market is also experiencing considerable growth, with a projected market share of approximately 28%. The region benefits from a strong healthcare system and an increasing focus on diabetes management initiatives. Rising awareness about diabetes care among the population and supportive government policies aimed at improving diabetes treatment are expected to propel the market forward. The Asia Pacific region, on the other hand, is anticipated to grow at the highest CAGR of over 6% during the forecast period, fueled by a rapidly growing diabetic population, increasing disposable incomes, and enhanced access to healthcare services. Countries like China and India are seeing a surge in demand for insulin syringes, driven by urbanization and lifestyle changes that contribute to diabetes prevalence.

Opportunities

The opportunities in the insulin syringes market are vast, particularly due to the increasing diabetes prevalence worldwide. As more individuals are diagnosed with diabetes, the demand for effective insulin delivery systems is expected to rise significantly. Furthermore, advancements in technology offer the potential for innovative product developments, such as integration with mobile health applications that track insulin usage and provide reminders. This convergence of healthcare and technology not only supports better patient outcomes but also fosters patient engagement in managing their condition. Companies that invest in research and development for smart insulin delivery systems stand to gain a competitive edge, catering to the tech-savvy demographics emerging within the diabetes population.

Moreover, the rising trend of personalized medicine presents a unique opportunity for the insulin syringes market. As healthcare continues to shift towards tailored treatment plans, the demand for customized insulin delivery solutions is likely to increase. This could involve developing syringes that accommodate specific patient needs, such as different insulin formulations or delivery rates. Additionally, partnerships between pharmaceutical companies, device manufacturers, and healthcare providers can encourage the development and distribution of innovative insulin delivery methods, ultimately improving patient access to necessary diabetes management tools. Expanding into underserved markets, particularly in developing regions, can also yield significant opportunities for growth as healthcare accessibility improves.

Threats

While the insulin syringes market is poised for growth, several threats could hinder its progress. One of the primary concerns is the increasing adoption of alternative diabetes management technologies, such as insulin pumps and continuous glucose monitoring systems, which may reduce the reliance on traditional insulin syringes. As these technologies become more accessible and affordable, they might shift patient preferences away from syringes, leading to potential market decline. Furthermore, competition from emerging players in the diabetes care sector can intensify, driving down prices and thereby impacting profit margins for established companies. The rapid pace of technological advancements could also present challenges for companies that struggle to keep up with evolving patient needs and expectations.

Regulatory challenges may also pose a significant threat to the insulin syringes market. Stringent regulations surrounding medical devices and pharmaceuticals can complicate the approval process for new products, leading to delays in market entry. Compliance with varying regulations across different regions can also increase operational complexities and costs for manufacturers. Additionally, the potential for product recalls due to safety concerns or manufacturing defects can negatively impact brand reputation and consumer confidence. Such challenges require continuous monitoring and adaptability from companies to ensure they remain competitive in the fast-evolving landscape of diabetes management.

Competitor Outlook

• BD (Becton, Dickinson and Company)
• Owen Mumford Ltd.
• Medtronic
• Hollister Incorporated
• Terumo Corporation
• Eli Lilly and Company
• Sanofi
• Roche Diagnostics
• Novo Nordisk
• Ypsomed AG
• Fresenius Kabi AG
• Smiths Medical
• Amgen Inc.
• Unomedical
• B. Braun Melsungen AG

The competitive landscape of the insulin syringes market is characterized by the presence of several key players, each striving to maintain a significant market share through innovation and strategic partnerships. Established companies, such as BD and Medtronic, leverage their extensive product portfolios and established relationships with healthcare providers to drive demand for their insulin delivery solutions. These firms are focusing on developing innovative products, including safety and smart insulin syringes, that align with evolving patient needs. Additionally, many players are investing in research and development to enhance their existing products and introduce new features that improve usability and safety for patients.

Emerging companies are also entering the insulin syringes market, often challenging established players by offering unique and cost-effective solutions. These companies tend to focus on niche segments, such as eco-friendly disposable syringes or specialized delivery systems for specific patient populations. Collaboration between manufacturers and healthcare providers is becoming increasingly common, enabling the development of tailored solutions that meet the needs of both patients and healthcare professionals. This trend is expected to foster innovation and drive competition within the market, ultimately benefiting consumers by providing a wider array of options for insulin delivery.

Furthermore, strategic acquisitions and partnerships are prevalent in the insulin syringes market, as companies aim to expand their market presence and enhance their capabilities. For instance, major pharmaceutical firms are acquiring smaller device manufacturers to integrate insulin delivery solutions into their diabetes management platforms. This consolidation trend can lead to increased efficiency and innovation, but it may also raise concerns about market monopolization. As the insulin syringes market continues to evolve, companies that prioritize patient-centered solutions and adaptability to market changes will likely emerge as leaders in this competitive landscape.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Sanofi
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Medtronic
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Amgen Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Unomedical
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Ypsomed AG
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Novo Nordisk
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Smiths Medical
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Fresenius Kabi AG
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Owen Mumford Ltd.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Roche Diagnostics
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Terumo Corporation
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 B. Braun Melsungen AG
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Eli Lilly and Company
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Hollister Incorporated
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 BD (Becton, Dickinson and Company)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Insulin Syringes Market, By Application
    • 6.1.1 Type 1 Diabetes
    • 6.1.2 Type 2 Diabetes
    • 6.1.3 Gestational Diabetes
    • 6.1.4 Insulin Resistance
    • 6.1.5 Prediabetes
  • 6.2 Insulin Syringes Market, By Product Type
    • 6.2.1 Standard Insulin Syringes
    • 6.2.2 Safety Insulin Syringes
    • 6.2.3 Smart Insulin Syringes
    • 6.2.4 Pen Needles
    • 6.2.5 Insulin Syringe with Needle
  • 6.3 Insulin Syringes Market, By Material Type
    • 6.3.1 Plastic Insulin Syringes
    • 6.3.2 Glass Insulin Syringes
    • 6.3.3 Metal Insulin Syringes
    • 6.3.4 Disposable Insulin Syringes
    • 6.3.5 Reusable Insulin Syringes
  • 6.4 Insulin Syringes Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Diabetes Clinics
    • 6.4.5 Home Healthcare

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Insulin Syringes Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Insulin Syringes market is categorized based on

By Product Type

• Standard Insulin Syringes
• Safety Insulin Syringes
• Smart Insulin Syringes
• Pen Needles
• Insulin Syringe with Needle

By Application

• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes
• Insulin Resistance
• Prediabetes

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Diabetes Clinics
• Home Healthcare

By Material Type

• Plastic Insulin Syringes
• Glass Insulin Syringes
• Metal Insulin Syringes
• Disposable Insulin Syringes
• Reusable Insulin Syringes

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• BD (Becton, Dickinson and Company)
• Owen Mumford Ltd.
• Medtronic
• Hollister Incorporated
• Terumo Corporation
• Eli Lilly and Company
• Sanofi
• Roche Diagnostics
• Novo Nordisk
• Ypsomed AG
• Fresenius Kabi AG
• Smiths Medical
• Amgen Inc.
• Unomedical
• B. Braun Melsungen AG